Watson's New Oxytrol Strategy: Specialty Care Market, Fewer Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is "not equipped to compete" with Pfizer (Detrol) and J&J (Ditropan XL) in the primary care market for overactive bladder therapies, CEO Chao says. Watson is terminating its agreement with contract sales organization Ventiv, which supplied 380 primary care reps for Oxytrol.
You may also be interested in...
Watson To Create Brand, Generic Unit Presidents Under Restructuring
The company has initiated an internal and external search to fill the new positions. As part of the reorganization, Watson President and COO Joseph Papa is leaving the company Nov. 19.
Watson To Create Brand, Generic Unit Presidents Under Restructuring
The company has initiated an internal and external search to fill the new positions. As part of the reorganization, Watson President and COO Joseph Papa is leaving the company Nov. 19.
Watson Seeks Co-Promotion Partner For Oxytrol In Primary Care Setting
The company is seeking a partner with "strong relationships" with high-volume prescribers of overactive bladder therapies in the primary care market. Watson wants to retain Oxytrol's position in primary care despite the company's intention to shift its marketing focus to specialty care.